Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.